Rain Therapeutics to Participate in H.C. Wainwright’s 3rd Annual Precision Oncology Virtual Conference

NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in H.C. Wainwright’s 3^rd Annual Precision Oncology Conference on November 14, 2022.

Company management will participate in one-on-one investor meetings, and Avanish Vellanki, CEO, will be participating in a fireside chat on Monday, November 14 at 1:00 PM ET. The webcast of the fireside chat is linked here.

If you would like to request a meeting with management, please contact your H.C. Wainwright representative.

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Investor Contact
Dan Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com